Compras y ventas de directivos de IDEXX Laboratories (IDXX)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de IDEXX Laboratories, Inc. (IDXX): ninguna compra y 9 ventas
59 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de IDEXX Laboratories, Inc. entre el 2025-08-26 y el 2026-09-09 (histórico de 15 meses): 0 compras y 9 ventas en mercado abierto, y 50 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $15,3M de Mazelsky Jonathan Jay el 2026-02-26.
Compras y ventas de directivos de IDEXX Laboratories en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de IDEXX Laboratories declararon 8 ventas por $37,7M en mercado abierto, y ninguna compra.
Quien más vendió fue Mazelsky Jonathan Jay (President and CEO): $15,3M en 1 venta, de 6 vendedores distintos.
La mayor operación del período fue una venta de $15,3M el 26 feb 2026, de Mazelsky Jonathan Jay (President and CEO). Formulario 4 en sec.gov (0000874716-26-000043).
Ninguna de las 8 ventas lleva en el Formulario 4 la marca de plan 10b5-1 (las ventas programadas con meses de antelación).
En los tres últimos meses hay 1 venta, frente a 0 en los tres anteriores. La última venta es del 4 sept 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. IDEXX Laboratories tiene más ventas que 27 de las otras 58, es la 19.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra.
Las 20 operaciones más importantes
Como IDXX no tiene compras en mercado abierto, la tabla empieza por sus ventas, de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 59 operaciones de IDXX en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-03-02 | Mazelsky Jonathan Jay | President and CEO | $15,3M | S — Venta en mercado abierto13 notas del Formulario 4 (texto original de la SEC, en inglés)F1 Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F3 Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F4 Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F5 Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F6 Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F7 Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F8 Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F9 Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F10 Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F11 Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F12 Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F13 Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-02-10 | 2026-02-11 | Fennell George | Executive Vice President | $7,3M | S — Venta en mercado abierto7 notas del Formulario 4 (texto original de la SEC, en inglés)F1 Represents the weighted average price of the shares sold ranging from a low of $642.595 to a high of $643.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 Represents the weighted average price of the shares sold ranging from a low of $643.65 to a high of $644.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F3 Represents the weighted average price of the shares sold ranging from a low of $644.75 to a high of $645.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F4 Represents the weighted average price of the shares sold ranging from a low of $645.80 to a high of $646.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F5 Represents the weighted average price of the shares sold ranging from a low of $646.825 to a high of $647.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F6 Represents the weighted average price of the shares sold ranging from a low of $648.02 to a high of $649.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F7 Represents the weighted average price of the shares sold ranging from a low of $649.05 to a high of $649.72 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2025-11-07 | 2025-11-10 | Hunt Nimrata | Executive Vice President | $6,6M | S — Venta en mercado abierto4 notas del Formulario 4 (texto original de la SEC, en inglés)F2 Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F3 Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F4 Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F5 Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-02-17 | 2026-02-19 | Erickson Michael G | Executive Vice President | $3,4M | S — Venta en mercado abierto5 notas del Formulario 4 (texto original de la SEC, en inglés)F1 Represents the weighted average price of the shares sold ranging from a low of $623.28 to a high of $624.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 Represents the weighted average price of the shares sold ranging from a low of $624.89 to a high of $625.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F3 Represents the weighted average price of the shares sold ranging from a low of $626.045 to a high of $628.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F4 Represents the weighted average price of the shares sold ranging from a low of $627.74 to a high of $628.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F5 Represents the weighted average price of the shares sold ranging from a low of $628.755 to a high of $629.615 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-02-26 | 2026-02-27 | Hunt Nimrata | Executive Vice President | $1,8M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 Represents the weighted average price of the shares sold ranging from a low of $661.35 to a high of $661.8275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2025-08-22 | 2025-08-26 | Szostak M Anne | Consejero | $1,4M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 Represents the weighted average price of the shares sold ranging from a low of $647.30 to a high of $647.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-09-04 | 2026-09-09 | Kingsley Lawrence D | Consejero | $1,2M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 Represents the weighted average price of the shares sold ranging from a low of $531.88 to a high of $532.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-03-03 | 2026-03-05 | Hunt Nimrata | Executive Vice President | $1,1M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-02-17 | 2026-02-19 | Vandebroek Sophie V. | Consejero | $920k | S — Venta en mercado abierto | SEC |
| 2025-11-07 | 2025-11-10 | Hunt Nimrata | Executive Vice President | $4,8M | M — Ejercicio de opcionesNota del Formulario 4 (texto original de la SEC, en inglés)F1 Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025. | SEC |
| 2026-02-26 | 2026-03-02 | Mazelsky Jonathan Jay | President and CEO | $3,3M | M — Ejercicio de opciones | SEC |
| 2026-02-17 | 2026-02-19 | Erickson Michael G | Executive Vice President | $914k | M — Ejercicio de opciones | SEC |
| 2026-02-10 | 2026-02-11 | Fennell George | Executive Vice President | $770k | M — Ejercicio de opciones | SEC |
| 2026-02-14 | 2026-02-17 | Hunt Nimrata | Executive Vice President | $726k | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F2 Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. | SEC |
| 2026-02-14 | 2026-02-17 | Erickson Michael G | Executive Vice President | $613k | F — Retención fiscal (acciones entregadas por impuestos)2 notas del Formulario 4 (texto original de la SEC, en inglés)F3 Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. F4 Includes 184 vested but deferred RSUs. | SEC |
| 2026-02-14 | 2026-02-17 | Mazelsky Jonathan Jay | President and CEO | $576k | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F2 Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. | SEC |
| 2026-02-14 | 2026-02-17 | Schreck Michael | Executive Vice President | $551k | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F2 Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. | SEC |
| 2026-02-19 | 2026-02-19 | Erickson Michael G | Executive Vice President | $547k | M — Ejercicio de opcionesNota del Formulario 4 (texto original de la SEC, en inglés)F6 Includes 184 vested but deferred restricted stock units. | SEC |
| 2025-08-22 | 2025-08-26 | Szostak M Anne | Consejero | $452k | M — Ejercicio de opciones | SEC |
| 2026-02-17 | 2026-02-19 | Vandebroek Sophie V. | Consejero | $316k | M — Ejercicio de opciones | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 26 ago 2025 y el 9 sept 2026 no consta ni una compra en mercado abierto de IDEXX Laboratories, Inc.: 9 ventas por $39,1M y cero dólares comprados.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de IDEXX Laboratories, Inc. salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| M | Ejercicio de opciones | 30 | $11,7M |
| F | Retención fiscal (acciones entregadas por impuestos) | 13 | $3,4M |
| S | Venta en mercado abierto | 9 | $39,1M |
| A | Adjudicación o premio de acciones | 4 | $100k |
| G | Regalo o donación | 3 | $0 |
| Total | Todo lo declarado en el período | 59 | $54,3M |
22 de las 59 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de IDEXX Laboratories, Inc. 16 personas o entidades distintas. De ellas, ninguna compró en mercado abierto y 7 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
De los 7 que vendieron en mercado abierto (9 ventas en total), los tres que más vendieron suman $32,2M de los $39,1M: el 82% del dinero en tres personas.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| Mazelsky Jonathan Jay | President and CEO | 6 | — | $15,3M (1) | 2026-03-02 |
| Hunt Nimrata | Executive Vice President | 6 | — | $9,5M (3) | 2026-03-05 |
| Fennell George | Executive Vice President | 7 | — | $7,3M (1) | 2026-06-02 |
| Erickson Michael G | Executive Vice President | 5 | — | $3,4M (1) | 2026-02-19 |
| Szostak M Anne | Consejero | 5 | — | $1,4M (1) | 2026-05-11 |
| Kingsley Lawrence D | Consejero | 3 | — | $1,2M (1) | 2026-09-09 |
| Vandebroek Sophie V. | Consejero | 3 | — | $920k (1) | 2026-05-11 |
| Hooley Joseph L | Consejero | 5 | — | — | 2026-08-03 |
Se enseñan los 8 que más dinero movieron, de 16. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue feb 2026: 0 compras y 5 ventas, por $28,7M. 10 de los 15 meses no tienen ninguna.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 1 | $1,4M |
| sept 2025 | 0 | $0 | 0 | $0 |
| oct 2025 | 0 | $0 | 0 | $0 |
| nov 2025 | 0 | $0 | 1 | $6,6M |
| dic 2025 | 0 | $0 | 0 | $0 |
| ene 2026 | 0 | $0 | 0 | $0 |
| feb 2026 | 0 | $0 | 5 | $28,7M |
| mar 2026 | 0 | $0 | 1 | $1,1M |
| abr 2026 | 0 | $0 | 0 | $0 |
| may 2026 | 0 | $0 | 0 | $0 |
| jun 2026 | 0 | $0 | 0 | $0 |
| jul 2026 | 0 | $0 | 0 | $0 |
| ago 2026 | 0 | $0 | 0 | $0 |
| sept 2026 | 0 | $0 | 1 | $1,2M |
| oct 2026 | 0 | $0 | 0 | $0 |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de IDEXX Laboratories, Inc. (IDXX) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
Ninguna de las 9 ventas de la tabla va marcada como programada (plan 10b5-1), la venta que se firma con meses de antelación y se ejecuta sola. IDEXX Laboratories no tiene ninguna compra en mercado abierto (código P) en el histórico, que es lo más común en el S&P 500: los directivos ya cobran en acciones. La última presentación es del 9 sept 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
14 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.